Nuveen LLC Makes New $561,000 Investment in Aura Biosciences, Inc. $AURA

Key Points

• Nuveen LLC has acquired a new stake in Aura Biosciences, purchasing 95,706 shares valued at approximately $561,000, representing about 0.19% ownership in the company.
• Research firms have issued positive ratings for Aura Biosciences, with JMP Securities and HC Wainwright providing price targets of $19.00 and $22.00, respectively, signaling a favorable outlook on the stock.
• The company reported earnings of ($0.47) per share for the last quarter, exceeding analyst expectations, with forecasts suggesting a projected -1.66 earnings per share for the current year.

Nuveen LLC acquired a new position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 95,706 shares of the company's stock, valued at approximately $561,000. Nuveen LLC owned approximately 0.19% of Aura Biosciences at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Levin Capital Strategies L.P. boosted its position in Aura Biosciences by 9.1% in the first quarter. Levin Capital Strategies L.P. now owns 1,360,768 shares of the company's stock worth $7,974,000 after purchasing an additional 113,149 shares during the last quarter. Regency Capital Management Inc. DE lifted its position in shares of Aura Biosciences by 23.0% in the first quarter. Regency Capital Management Inc. DE now owns 749,482 shares of the company's stock valued at $4,392,000 after acquiring an additional 140,058 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company's stock worth $3,212,000 after acquiring an additional 118,000 shares during the last quarter. Northern Trust Corp boosted its holdings in Aura Biosciences by 6.3% in the fourth quarter. Northern Trust Corp now owns 387,269 shares of the company's stock valued at $3,183,000 after purchasing an additional 23,006 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Aura Biosciences by 25.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 365,824 shares of the company's stock valued at $3,007,000 after acquiring an additional 73,062 shares during the period. Hedge funds and other institutional investors own 96.75% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. JMP Securities reissued a "market outperform" rating and issued a $19.00 price objective on shares of Aura Biosciences in a research report on Friday, May 23rd. Zacks Research upgraded shares of Aura Biosciences from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Wednesday, August 13th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $22.00.

Insider Transactions at Aura Biosciences

In other news, SVP Amy Elazzouzi sold 7,722 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the completion of the sale, the senior vice president directly owned 86,558 shares of the company's stock, valued at $579,938.60. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.30% of the stock is owned by corporate insiders.

Aura Biosciences Price Performance

Aura Biosciences stock traded up $0.02 during mid-day trading on Monday, reaching $6.50. The stock had a trading volume of 148,510 shares, compared to its average volume of 212,811. The company has a market capitalization of $403.78 million, a price-to-earnings ratio of -3.32 and a beta of 0.45. The company has a 50-day moving average price of $6.64 and a two-hundred day moving average price of $6.36. Aura Biosciences, Inc. has a one year low of $4.34 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, equities research analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.